gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news genet medicin zolgensma good launch data
highlight week octob octob novarti unrat report result includ sale
gt zolgensma royalti owe buy chardan top pick report
zolgensma sale mm mm calcul correspond mm royalti
revenu though earli zolgensma narrow initi label unrat spinraza
outpac spinraza launch although demand mechan could lead flat sale acceler
axov gene therapi buy present european societi gene cell therapi esgct annual
congress barcelona data investigator-initi trial patient gangliosidosi tay-sach diseas
treat dose vg gene therapi gt patient
month old sever diseas time dose children hospit philadelphia infant test neuromuscular
disord chop-intend score increas baselin month post-treat -hexosaminidas
hex enzym activ cerebrospin fluid csf increas baselin month post-treat
patient month old pre-symptomat time dose chop-intend score increas
baselin month post-treat hex enzym activ csf increas normal
normal baselin per manag regard hex enzym activ sustain level
normal enzym activ expect correl clinic meaning effect buy
announc bayer unrat privat joint ventur crispr tx bayer
oper direct manag crispr tx transact expect close upon close
casebia continu develop therapeut hemophilia ophthalmolog autoimmun
diseas bayer right opt product upon ind submiss nih melinda
gate foundat announc mm collabor fund develop sickl cell diseas scd
hiv ensur avail global particularli low-resourc set sub-saharan africa
collabor focu advanc clinic trial us sub-saharan africa year
chardan annual genet medicin confer on-line survey avail
chardan annual genet medicin confer held new york citi octob
repres privat public compani investor around globe key opinion leader
total attende took part becom largest sell-sid confer focus field
genet medicin part continu coverag space post-confer survey avail
look forward octob novemb octob aacr-nci-eortc intern confer
molecular target cancer therapeut held boston agenda includ ksq therapeut
privat mina privat rubiu unrat octob dia/fda
oligonucleotide-bas confer take place bethesda maryland agenda includ avid
therapeut unrat unrat octob novemb north american cystic
fibrosi confer take place nashvil tennesse program includ abeona therapeut unrat
arrowhead pharmaceut unrat compani report result
unrat octob et medicin compani buy chardan top pick
et buy octob et
weekli price move vivo genet medicin aav srna mrna vivo gene edit
upcom chardan genet medicin event contact chardan rsvp
pleas refer import disclosur inform regul analyst certif found page report
crsp buy crsp absorb casebia bayer keep opt-in right octob livshit
crispr announc bayer unrat plan privat establish
joint ventur jv compani oper direct manag crispr
anticip close transact casebia would continu focu lead program hemophilia
ophthalmolog autoimmun diseas bayer would opt-in right product time ind submiss
term transact disclos subject negoti per manag
expect major impact crispr cash runway
move potenti acceler develop casebia program us casebia ex vivo program
particular would benefit crispr tx clinic expertis hematopoiet stem cell cell-bas
therapi crispr access casebia nucleas deliveri tech/know-how
term jv closer integr could bolster develop crispr vivo program
note addit aforement opt-in right bayer retain exposur crispr gene edit space via
acquisit bluerock announc august
buy pt rais pt model updat pipelin program octob naka
octob arrowhead host day new york citi key take-away success compani
rapidli advanc pipelin asset translat numer potenti value-cr
clinic data point next sever year includ comprehens look singl ascend dose data
healthi volunt phase studi rnai therapeut
target dyslipidemia hypertriglyceridemia late breaker present american heart
associ aha scientif session novemb base benign safeti data target knockdown data
present thu far phase trial increas probabl success program model
increas pt
key highlight day deeper dive compani aro-hsd program target liver
hepatocyt cell knockdown hydroxysteroid dehydrogenas involv metabol
hormon fatti acid bile acid loss-of function mutat shown protect
develop alcohol relat non-alcohol relat liver diseas like nash
key highlight advanc rnai target outsid liver compani expect file cta
renal cell carcinoma file cta aro-enac cystic fibrosi arrowhead also
announc expect advanc muscl target rnai still undisclos diseas around
novarti unrat report result includ sale gt zolgensma royalti owe
report zolgensma sale mm mm thu translat
mm royalti revenu recal zolgensma approv fda may
zolgensma sale report novarti result result repres look ramp
offer follow reason zolgensma like see sale momentum ultim pass
mm global sale total unrat spinraza
 zolgensma launch outpac sma-product spinraza think zolgensma superior profil
inde novarti state zolgensma see switch spinraza
 zolgensma see acceler row approv eu japan
 novarti global infrastructur china vastli exce
 zolgensma label expans patient year age acceler sale
 us zolgensma access though broad expand medicaid screen reason
buy ov program enter clinic octob livshit
replimun announc enrol patient phase studi oncolyt viru
immunotherapi asset immulyt platform like hsv-base oncolyt viru express galv-
gp gm-csf stimul immun respons upon intratumor administr howev addit
encod antibody-lik molecul
page
studi evalu /- bristol-my squibb unrat nivolumab opdivo advanc solid
tumor phase studi yet list clinicaltri gov focus safeti toler determin
optim dose singl agent combo set
us system deliveri like nivolumab gener well toler togeth intratumor
deliveri could yield efficaci benefit ipilimumab nivolumab combo limit toxic
anticip initi phase safety/toler data
buy pt detail model pd franchis octob amusa
axov gene therapi present european societi gene cell therapi esgct annual congress
barcelona data patient gangliosidosi treat gt patient
investigator-initi trial treat dose vg
us data discuss show evid clinic stabil patient sever diseas
prevent diseas progress pre-symptomat patient support prior comment
well transform axov valuat follow reason
 fatal natur infantil form diseas life expect year
 low amount enzym product gt may abl transform clinic outcom
 therapi approv disease-modifi treatment
news well recent axov pipelin posit increas price target
crispr gene edit prime edit cut crispr pie octob livshit
past week world introduc prime edit new twist crispr genom edit public
octob studi journal natur approach introduc precis edit avoid double-
strand dna break garner substanti media attent mani question aris fit broader
genom edit landscap whether supersed genom edit approach
work came david liu group broad institut mit harvard notabl liu
gave take new technolog discuss potenti applic remain question
key develop crispr base edit co-found privat
 prime edit directli write new dna sequenc desir locat genom without
 good per studi rang edit theori use correct known
mutat associ human diseas base pathogen variant catalog clinvar databas
 prime edit mani thing current iter way insert long
creat double-strand break time
dna sequenc entir gene desir genom site
 open question effici deliveri off-target edit
genet medicin news octob octob
agtc buy present data ocular gt efficaci nhp presenc anti-aav nab octob
unrat present preclin data aavhsc-bas gt program pku mld octob
unrat publish nch preclin data gt dmd octob
sight fp neutral report cash posit updat regulatori interact octob
unrat announc ind clearanc ex vivo lentivir gt pkd octob
unrat announc appoint holli may chief commerci offic octob
ortx unrat present data ex vivo lentivir gt mld use cryopreserv octob
orchard present collabor san raffaele-telethon institut gene therapi sr-
tiget esgct data phase ii trial cryopreserv formul ex vivo lentivir gt
treatment metachromat leukodystrophi mld orchard track submit europ
bla us approxim year later
early-onset late infantil earli juvenil patient mld receiv intraven infus
cryopreserv cell gene-correct time follow rang month month median
follow year result show stabl level engraft measur percentag transduc
cell vector copi number vcn bone marrow restor arylsulfatase-a arsa enzym
page
activ peripher blood csf normal supra-norm level importantli result similar
seen patient previous receiv fresh formul
per manag patient treat cryopreserv formul orchard ex vivo across
clinic program cryopreserv may facilit global commerci allow gene-correct cell
frozen ship site patient administr thaw treatment thu allevi need
patient travel special site receiv treatment facilit global patient access
unrat announc ema approv refin spec ex vivo lenti gt zynteglo octob
oncoru privat announc appoint john mccabe chief offic octob
unrat present preclin data aav-bas canavan diseas octob
buy receiv track design mrna tx propion acidemia octob
unrat announc appoint kyle jenn chief commerci offic octob
nih announc melinda gate foundat mm collab scd hiv octob
nih announc collabor melinda gate foundat develop sickl cell diseas
scd hiv parti contribut mm goal fund develop
make global avail includ low-resourc set collabor focu advanc safe
effect durabl gene-bas cure clinic trial unit state relev countri sub-saharan
africa within next seven year
press releas touch theme across gt develop complex expens thu
readili avail hospit develop nation howev signific percentag patient need scd
hiv live develop world patient hiv live develop nation sub-saharan africa
case scd sub-saharan africa consequ find way make cur treatment
avail low-resourc set crucial
ocgn unrat announc appoint jessica crespo control octob
unrat report result provid busi updat octob
unrat announc plan departur chief strategi offic jeffrey walsh octob
selb unrat present data immtor mous model mma octob
mgh publish aav capsid better transgen express neuron octob
buy present preclin gene edit data aatd ph solid tumor octob
unrat receiv odd ex vivo lentivir gt gaucher diseas octob
viralgen privat announc plan mm gt manufactur plant spain octob
neutral present data pi/ii trial gt batten diseas octob
akouo privat announc appoint dr rabia gurs ozden chief develop offic octob
unrat present long-term data pi/ii trial ex vivo lentivir gt fa octob
unrat present data trial gt ptc-aadc aadc defici octob
present child neurolog societi annual meet long-term data trial
gt -aadc treatment l-amino acid decarboxylas aadc defici plan submit
bla fda
patient treat ptc-aadc across separ trial result show month post-
treatment intent-to-treat popul mean patient bodi weight increas
frequenc oculogyr crise involuntari upward eye movement reduc frequent report
advers event observ patient dyskinesia patient mild moder resolv
month post-treat
addit analysi show sustain effect treatment year includ clinic meaning improv
motor cognit languag mileston note analysi present build data previous present
subsequ acquir april american academi neurolog
neutral dose pt cohort pi trial gt wamd octob
page
unrat dose patient pi trial oncolyt viru treat glioblastoma octob
ancn unrat announc departur dr stephen hoffman board director octob
 pittsburgh publish oncolyt hsv arm matrix metalloproteinas gbm octob
unrat announc price mm initi public offer octob
ucsf publish convertiblecar-t ccar-t approach treat latent hiv octob
unrat report result provid busi updat octob
unrat announc departur cso gener counsel head corp strategi octob
mass publish gt protect noise-induc cochlear synaptopathi octob
unrat present preclin data aavhsc-bas gene edit candid pku octob
mayo clinic publish cocain hydrolas gt cocain addict octob
compani mention report
page
select catalyst genet medicin coverag
figur regenxbio replimun solid uniqur expect import data read-out
aro-aat initi phase ii/iii studi liver diseas
lumasiran initi illuminate-c phase trial
initi phase i/ii clinic trial huntington diseas
initi phase i/ii trial dmd nationwid children hospit
report interim efficaci readout phase oval trial ovarian cancer
report dose escal data pi/ii trial achm
dcr-hbv anticip first interim data clinic trial hbv
provid initi data phase trial gangliosidosi
axo-lenti-pd report data cohort sunrise-pd phase ii trial
submit ind methylmalon acidemia mma
present data phase portion solid tumor trial /- nivolumab
file ind phase ii studi diabet retinopathi dr
present interim data pi/ii studi mp ii pi studi mp
present interim data cohort steroid prophyl pi/ii studi hofh
file ind batten diseas
top-lin phase ii data treat deb patient chronic wound
initi dose phase trial hemophilia
initi patient dose brillianc phase i/ii trial
report result phase i/ii ignit dmd trial
initi phase iib studi wet
lumasiran present top-line data illuminate-a phase trial
vutrisiran initi helios-b phase studi cardiomyopathi attr amyloidosi
inclisiran file nda hypercholesterolemia
file ind huntington diseas program
present preclin data new gt program fabri pomp defici
provid follow-up data piib dose-confirm studi hemb
file ind cta pomp diseas
dose patient phase studi mp
provid updat phase i/ii studi hemophilia
declar develop candid aml
initi phase trial dystroph epidermolysi bullosa deb
page
select catalyst outsid genet medicin coverag
dtx provid phase i/ii cohort data ornithin transcarbamylas defici
valrox submit bla pend fda feedback hemophilia
initi pivot phase trial rdeb
initi phase data patient leukocyt adhes deficiency-i lad-i
report initi phase data process fanconi anemia
suvodirsen interim data open-label extens studi dmd
initi phase studi pyruv kinas defici pkd
initi us phase ii studi fanconi anemia
initi phase i/ii trial parkinson diseas mutat
initi phase ib trial beta-thalassemia
initi phase trial multipl myeloma
initi clinic trial charcot-marie-tooth type
file approv transit clinic trial platform manufactur
micro-dystrophin initi pivot trial duchenn muscular dystrophi
initi phase ii studi overact bladder
initi phase i/ii studi best diseas
micro-dystrophin initi confirmatori trial commerci materi dmd
begin patient dose phase trial
file ind inherit amyotroph later sclerosi
tegsedi expect approv brazil hattr amyloidosi
 anticip data readout phase trial hd
ptc-aadc file bla aromat l-amino acid decarboxylas aadc defici
ptc-fa file ind friedreich ataxia fa enter clinic
sea-bcma report preliminari phase dose escal data r/r mm
lentiglobin initi phase studi sickl cell diseas
zynteglo initi roll bla submiss fda tdt
report initi data phase i/ii trial phenylketonuria pku
rituximab report preliminari phase cohort data r/r nhl
file ind gangliosidosi
figur plan file bla aadc defici
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl neutral
figur select price movement week end oct vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm abeona genet therapytickerratingccm ptupsideclosechang changemc mm gene editingtickerratingccm ptupsideclosechang changemc mm sangamo pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note though avx nite acquir continu includ exhibit reflect valu creation sub-sector
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav gt space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof genet technolog privat aav-bas genetherapi molecular ask estev horama stride tamid technolog
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi excis exon feldan recombinet trucod gene repair verv technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
ultragenyx genetx
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
